162 related articles for article (PubMed ID: 1890154)
1. Ras oncogene mutations in benign and malignant thyroid neoplasms.
Karga H; Lee JK; Vickery AL; Thor A; Gaz RD; Jameson JL
J Clin Endocrinol Metab; 1991 Oct; 73(4):832-6. PubMed ID: 1890154
[TBL] [Abstract][Full Text] [Related]
2. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis.
Namba H; Rubin SA; Fagin JA
Mol Endocrinol; 1990 Oct; 4(10):1474-9. PubMed ID: 2283998
[TBL] [Abstract][Full Text] [Related]
3. Ras mutations in human pituitary tumors.
Karga HJ; Alexander JM; Hedley-Whyte ET; Klibanski A; Jameson JL
J Clin Endocrinol Metab; 1992 Apr; 74(4):914-9. PubMed ID: 1312542
[TBL] [Abstract][Full Text] [Related]
4. Specific pattern of RAS oncogene mutations in follicular thyroid tumors.
Vasko V; Ferrand M; Di Cristofaro J; Carayon P; Henry JF; de Micco C
J Clin Endocrinol Metab; 2003 Jun; 88(6):2745-52. PubMed ID: 12788883
[TBL] [Abstract][Full Text] [Related]
5. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan.
Liu RT; Hou CY; You HL; Huang CC; Hock-Liew ; Chou FF; Wang PW; Cheng JT
Thyroid; 2004 Aug; 14(8):616-21. PubMed ID: 15320975
[TBL] [Abstract][Full Text] [Related]
6. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area.
Shi YF; Zou MJ; Schmidt H; Juhasz F; Stensky V; Robb D; Farid NR
Cancer Res; 1991 May; 51(10):2690-3. PubMed ID: 2021946
[TBL] [Abstract][Full Text] [Related]
7. Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues.
Capella G; Matias-Guiu X; Ampudia X; de Leiva A; Perucho M; Prat J
Diagn Mol Pathol; 1996 Mar; 5(1):45-52. PubMed ID: 8919545
[TBL] [Abstract][Full Text] [Related]
8. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin.
Motoi N; Sakamoto A; Yamochi T; Horiuchi H; Motoi T; Machinami R
Pathol Res Pract; 2000; 196(1):1-7. PubMed ID: 10674266
[TBL] [Abstract][Full Text] [Related]
9. N-ras 61 oncogene mutations in Hürthle cell tumors.
Schark C; Fulton N; Jacoby RF; Westbrook CA; Straus FH; Kaplan EL
Surgery; 1990 Dec; 108(6):994-9; discussion 999-1000. PubMed ID: 2247846
[TBL] [Abstract][Full Text] [Related]
10. Ha-ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors.
Bouras M; Parvaz P; Berger N; Paulin C; Revol A
Ann Biol Clin (Paris); 1995; 53(10-11):549-55. PubMed ID: 8787281
[TBL] [Abstract][Full Text] [Related]
11. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.
Fukahori M; Yoshida A; Hayashi H; Yoshihara M; Matsukuma S; Sakuma Y; Koizume S; Okamoto N; Kondo T; Masuda M; Miyagi Y
Thyroid; 2012 Jul; 22(7):683-9. PubMed ID: 22650231
[TBL] [Abstract][Full Text] [Related]
12. Presence of mutations in all three ras genes in human thyroid tumors.
Suarez HG; du Villard JA; Severino M; Caillou B; Schlumberger M; Tubiana M; Parmentier C; Monier R
Oncogene; 1990 Apr; 5(4):565-70. PubMed ID: 2183158
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
14. Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors.
Challeton C; Bounacer A; Du Villard JA; Caillou B; De Vathaire F; Monier R; Schlumberger M; Suárez HG
Oncogene; 1995 Aug; 11(3):601-3. PubMed ID: 7630645
[TBL] [Abstract][Full Text] [Related]
15. ras mutations and expression in head and neck squamous cell carcinomas.
Yarbrough WG; Shores C; Witsell DL; Weissler MC; Fidler ME; Gilmer TM
Laryngoscope; 1994 Nov; 104(11 Pt 1):1337-47. PubMed ID: 7968162
[TBL] [Abstract][Full Text] [Related]
16. K-ras activation in premalignant and malignant epithelial lesions of the human uterus.
Enomoto T; Inoue M; Perantoni AO; Buzard GS; Miki H; Tanizawa O; Rice JM
Cancer Res; 1991 Oct; 51(19):5308-14. PubMed ID: 1913654
[TBL] [Abstract][Full Text] [Related]
17. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.
Lemoine NR; Mayall ES; Wyllie FS; Williams ED; Goyns M; Stringer B; Wynford-Thomas D
Oncogene; 1989 Feb; 4(2):159-64. PubMed ID: 2648253
[TBL] [Abstract][Full Text] [Related]
18. Polymerase chain reaction/sequencing analysis of ras mutations in paraffin-embedded tissues as compared with 3T3 transfection and polymerase chain reaction/sequencing of frozen tumor deoxyribonucleic acids.
Goodrow TL; Prahalada SR; Storer RD; Manam SV; Leander KR; Kraynak AR; van Zwieten MJ; Nichols WW; Bradley MO
Lab Invest; 1992 Apr; 66(4):504-11. PubMed ID: 1583889
[TBL] [Abstract][Full Text] [Related]
19. Variability of Ha-ras (codon 12) proto-oncogene mutations in diverse thyroid cancers.
Bouras M; Bertholon J; Dutrieux-Berger N; Parvaz P; Paulin C; Revol A
Eur J Endocrinol; 1998 Aug; 139(2):209-16. PubMed ID: 9724079
[TBL] [Abstract][Full Text] [Related]
20. N-ras mutation of thyroid tumor with special reference to the follicular type.
Oyama T; Suzuki T; Hara F; Iino Y; Ishida T; Sakamoto A; Nakajima T
Pathol Int; 1995 Jan; 45(1):45-50. PubMed ID: 7704243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]